Literature DB >> 11216405

Plasma cholinesterase activity in patients with uterine cervical cancer during radiotherapy.

V Bradamante1, E Smigovec, D Buković, J Geber, D Matanić.   

Abstract

The objectives of this study were to investigate: 1) the activity of pseudocholinesterase (PChE) in patients with uterine cervical cancer in different stages (uterine cervical carcinoma in stages II b and III and recurrent cervical carcinoma in stages III and IV a,b) and to compare it to the enzyme activity in patients with benign tumour of the uterus, and 2) the effects of radiotherapy on enzyme activity in those patients with uterine cervical carcinoma for which the chosen treatment was radical radiotherapy. Thirty patients with uterine cervical carcinoma in stages II b and III (Group A), sixteen patients with recurrent cervical carcinoma in stages III and IV a,b (Group B) and thirty-eight patients with benign tumours of the uterus (control, Group C) were evaluated and their PChE activity was determined prior to any treatment (pre-therapy enzyme activity). All eighty-four patients were free of any liver disease. The results have shown that the patients of Group A had the pre-therapy PChE activity practically identical to those in group C, but patients of Group B had significantly lower values of PChE with respect to enzyme activities of Groups A and C (p < 0.001). That is to say, PChE activity was influenced by the extent to which the malignancy had spread. Radical radiotherapy (up to 8 weeks in doses higher than 50 Gy into point A; average 80 Gy) which was the chosen treatment only for patients from group A did not cause a significant inhibition of PChE activity in any patients in comparison with their control values. With regard to the role of PChE in hydrolysis of succinylcholine, our results about the influence of the malignant disease and the radiotherapy on PChE activity are clinically significant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11216405

Source DB:  PubMed          Journal:  Coll Antropol        ISSN: 0350-6134


  6 in total

1.  Protein thiols and butryrylcholinestrase in saliva of oral cancer patients.

Authors:  Yousef Rezaei Chianeh; Rashmi Manjunath; Krishnananda Prabhu; Donald Fernandes; M Vidyasagar; Asha Kamath
Journal:  Indian J Clin Biochem       Date:  2013-06-15

2.  Alterations of serum cholinesterase in patients with gastric cancer.

Authors:  Shan-Zhi Gu; Xin-Han Zhao; Ping Quan; Sheng-Bin Li; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

3.  Significance of serum butyrylcholinesterase levels in oral cancer.

Authors:  K Prabhu; D Naik; S Ray; A Rao; A Kamath
Journal:  Australas Med J       Date:  2011-07-31

4.  Estimation of Serum Butyryl Cholinesterase in Patients with Oral Squamous Cell Carcinoma: A Cross-Sectional Study.

Authors:  Keerthi K Nair; Gujjar Vittobarao Pramod; Kanad Chaudhuri; Lingappa Ashok
Journal:  J Clin Diagn Res       Date:  2017-07-01

5.  The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy.

Authors:  Nina Poetsch; Alina Sturdza; Stefanie Aust; Stephan Polterauer; Christoph Grimm; Richard Schwameis; Richard Pötter; Heinz Koelbl; Alexander Reinthaller; Veronika Seebacher
Journal:  Strahlenther Onkol       Date:  2019-02-08       Impact factor: 3.621

6.  Cholinesterase is Associated With Prognosis and Response to Chemotherapy in Advanced Gastric Cancer.

Authors:  Yanzhi Bi; Junling Zhang; Dongxiang Zeng; Lili Chen; Wei Ye; Quanliang Yang; Yang Ling
Journal:  Pathol Oncol Res       Date:  2021-03-25       Impact factor: 3.201

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.